Updates in Healthcare Maintenance and Monitoring of Children with Inflammatory Bowel Disease in the Era of Biologic Therapies
- 8 Downloads
Purpose of Review
As the therapeutic armamentarium for the management of pediatric inflammatory bowel disease (IBD) expands, it is increasingly challenging for pediatric gastroenterologists and pediatric primary care providers to stay abreast of the available therapies and the associated side effects, required monitoring, and specific health maintenance needs for these patients. Here, we review the currently available therapies and general treatment strategies for the management of pediatric IBD, along with clinical considerations in the context of general pediatric care.
The number of therapies for the management of IBD has grown rapidly in recent years. While pediatric providers have become adept with the use of anti-tumor necrosis factor-alpha therapies, and large safety registries have helped us understand the risks of these biologic agents, there is much left to learn about the pediatric use of newer therapies, such as vedolizumab, ustekinumab, and tofacitinib.
Biologic therapies and other targeted anti-inflammatory therapies are increasingly used in children with IBD. Pediatric primary care providers and pediatric gastroenterologists must be aware of the risks, benefits, and additional implications of these therapies. Vaccination strategies, recognition and management of routine or opportunistic infections, assessment of rashes, and cancer screening represent areas of particular importance in these children.
KeywordsInflammatory bowel disease (IBD) Infliximab Adalimumab Ustekinumab Vedolizumab Tofacitinib
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.• Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112(7):1120–34 This study serves as an important epidemiologic investigation into the rising prevalence of pediatric inflammatory bowel disease in a population with high incidence. In particular, it highlights the rapid increase in incidence in very young children.PubMedPubMedCentralCrossRefGoogle Scholar
- 18.• Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–8 e3 This study provides important insight into the importance of proactive drug monitoring, which is being adopted in clinical practice with increasing frequency.PubMedPubMedCentralCrossRefGoogle Scholar
- 19.•• Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Clinical Guidelines. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34 These societal guidelines are and important summary of the available data on therapeutic drug monitoring in IBD, particularly in reference to anti-TNF therapies.PubMedCrossRefGoogle Scholar
- 20.Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(2):361–8.PubMedCrossRefGoogle Scholar
- 22.• Lane ER, Lee D, Suskind DL. Dietary therapies in pediatric inflammatory bowel disease: an evolving inflammatory bowel disease paradigm. Gastroenterol Clin N Am. 2017;46(4):731–44This article provides a thorough review of the dietary therapies that are part of the therapeutic approach for pediatric inflammatory bowel disease and may serve as a good supplement to our current review, which focuses primarily on medical.Google Scholar
- 25.Ardura MI, Kim SC. Infectious complications of pediatric inflammatory bowel disease. In: Mamula P, Grossman AB, Baldassano RN, Kelsen JR, Markowitz JE, editors. Pediatric inflammatory bowel disease. 3rd ed. Cham: Springer International Publishing; 2017.Google Scholar
- 34.• Click B, Regueiro M. Managing risks with biologics. Curr Gastroenterol Rep. 2019;21(2):1 This recent review provides a thoughtful overview of the risks and considerations that clinicians must be aware of in patients with IBD being treated with biologic therapies. It is one of the few reviews that addressess the risks of newer biologic thereapies.PubMedCrossRefGoogle Scholar
- 36.Takeda Pharmaceuticals America, Inc. Entyvio (vedolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf. Revised May 2014. Accessed June 4, 2019.
- 37.Am Acad Pediatr Immunization and Other Considerations in Immunocompromised Children. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2018; 72–91.Google Scholar
- 38.General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). https://cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. Revised April 20, 2017. Accessed June 9, 2019. [Internet].
- 41.Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, et al. Erratum to increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018.Google Scholar
- 46.Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019.Google Scholar
- 49.Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–97 e10.PubMedCrossRefGoogle Scholar
- 50.• Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–51 This study highlights the favorable safety profile of vedolizumab therapy in patients with IBD. It provides a comprehensive review of adverse events of interest and provides clinicians with data from a large cohort of patients that can aid clinical decision-making.PubMedCrossRefGoogle Scholar
- 53.• Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60 This study reviews the clinical trial data leading to the approval for ustekinumab for the induction and maintenance of Crohn’s disease and provides important insight into the efficacy and safety of this therapy.PubMedCrossRefGoogle Scholar
- 54.Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2019.Google Scholar
- 55.• Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36 This study reviews the clinical trial data leading to the approval for tofacitinib for the induction and maintenance of ulcerative colitis and provides important insight into the efficacy and safety of this therapy.PubMedCrossRefGoogle Scholar
- 56.Sandborn WJ, Panes J, D’Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2018.Google Scholar
- 62.Am Acad Pediatr Summaries of Infectious Diseases. In: Kimberlin DW BM, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2018; 711–718.Google Scholar
- 63.Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-alpha inhibitors. J Pediatr Gastroenterol Nutr. 2016;63(1):130–55.PubMedCrossRefGoogle Scholar
- 64.•• Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901–14 e3 This important study is the largest study examining the safety of anti-TNFα therapies in pediatric IBD to date. Its findings provide valuable information for clinicians to discuss with their patients when considering the risks of infliximab and thiopurines in the management of pediatric IBD.PubMedCrossRefGoogle Scholar
- 72.Janssen Biotech, Inc. Remicade (infliximab) [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf. Revised November 2013. Accessed June 13, 2019.
- 73.Janssen Biotech, Inc. STELARA (ustekinumab) [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761044Orig1s000Lbl.pdf. Revised September 2016. Accessed June 13, 2019.
- 74.Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019.Google Scholar